JP2020531030A5 - - Google Patents

Info

Publication number

JP2020531030A5

JP2020531030A5 JP2020511529A JP2020511529A JP2020531030A5 JP 2020531030 A5 JP2020531030 A5 JP 2020531030A5 JP 2020511529 A JP2020511529 A JP 2020511529A JP 2020511529 A JP2020511529 A JP 2020511529A JP 2020531030 A5 JP2020531030 A5 JP 2020531030A5

Authority

JP

Japan

Prior art keywords

glp

seq

amino acid

acid sequence

peptibody

Prior art date

2018-08-21

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 108010088406 Glucagon-Like Peptides Proteins 0.000 claims description 129
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 44
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 29
• 210000000813 small intestine Anatomy 0.000 claims description 28
• 229920001184 polypeptide Polymers 0.000 claims description 27
• 239000002243 precursor Substances 0.000 claims description 27
• 102000004196 processed proteins & peptides Human genes 0.000 claims description 27
• 102000040430 polynucleotide Human genes 0.000 claims description 16
• 108091033319 polynucleotide Proteins 0.000 claims description 16
• 239000002157 polynucleotide Substances 0.000 claims description 16
• 239000008194 pharmaceutical composition Substances 0.000 claims description 12
• 210000004027 cell Anatomy 0.000 claims description 11
• 230000005855 radiation Effects 0.000 claims description 11
• 210000001035 gastrointestinal tract Anatomy 0.000 claims description 9
• BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 claims description 8
• 206010023129 Jaundice cholestatic Diseases 0.000 claims description 6
• 201000005267 Obstructive Jaundice Diseases 0.000 claims description 6
• 206010049416 Short-bowel syndrome Diseases 0.000 claims description 6
• 230000006378 damage Effects 0.000 claims description 6
• 208000004232 Enteritis Diseases 0.000 claims description 5
• 230000007358 intestinal barrier function Effects 0.000 claims description 5
• 238000010521 absorption reaction Methods 0.000 claims description 4
• 230000002708 enhancing effect Effects 0.000 claims description 4
• 230000031891 intestinal absorption Effects 0.000 claims description 4
• 230000008520 organization Effects 0.000 claims description 4
• 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
• 150000003839 salts Chemical class 0.000 claims description 4
• 210000002966 serum Anatomy 0.000 claims description 4
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
• 208000006784 Cutaneous Fistula Diseases 0.000 claims description 3
• 208000019155 Radiation injury Diseases 0.000 claims description 3
• 230000006907 apoptotic process Effects 0.000 claims description 3
• 210000001072 colon Anatomy 0.000 claims description 3
• 230000035876 healing Effects 0.000 claims description 3
• 230000000968 intestinal effect Effects 0.000 claims description 3
• 230000001737 promoting effect Effects 0.000 claims description 3
• 238000013268 sustained release Methods 0.000 claims description 3
• 239000012730 sustained-release form Substances 0.000 claims description 3
• 206010070545 Bacterial translocation Diseases 0.000 claims description 2
• 230000007375 bacterial translocation Effects 0.000 claims description 2
• 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 2
• 230000003111 delayed effect Effects 0.000 claims description 2
• 230000001419 dependent effect Effects 0.000 claims description 2
• 238000013265 extended release Methods 0.000 claims description 2
• 230000002550 fecal effect Effects 0.000 claims description 2
• 210000004051 gastric juice Anatomy 0.000 claims description 2
• 238000001802 infusion Methods 0.000 claims description 2
• 238000002347 injection Methods 0.000 claims description 2
• 239000007924 injection Substances 0.000 claims description 2
• 239000007788 liquid Substances 0.000 claims description 2
• 235000016236 parenteral nutrition Nutrition 0.000 claims description 2
• 230000028327 secretion Effects 0.000 claims description 2
• 210000002700 urine Anatomy 0.000 claims description 2
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
• 239000000203 mixture Substances 0.000 claims 22
• 230000029087 digestion Effects 0.000 claims 1
• 238000000034 method Methods 0.000 description 96
• 238000004113 cell culture Methods 0.000 description 1